ALN-961583

ALN-961583 is an investigational, intrathecally administered small interfering RNA (siRNA) therapeutic developed by Alnylam Pharmaceuticals for the treatment of cerebral amyloid angiopathy (CAA). The drug is designed to target and silence the messenger RNA (mRNA) encoding the amyloid precursor protein (APP), thereby reducing the synthesis of APP and the subsequent generation of amyloid-beta (Aβ) peptides. By lowering Aβ levels in the central nervous system, ALN-961583 aims to prevent or reduce the deposition of amyloid in the walls of the brain's blood vessels, which is the primary cause of vascular fragility, microhemorrhages, and cognitive impairment in patients with sporadic or hereditary (Dutch-type) CAA. The therapeutic utilizes Alnylam's C16-conjugate technology, which enhances delivery and uptake into the brain and spinal cord following intrathecal administration.